Amylin receptor agonism.
Activating amylin and calcitonin-family receptors to promote meal-ending satiation.
Amylin, also called islet amyloid polypeptide, is co-secreted with insulin from pancreatic beta cells in response to a meal. It does not act through a dedicated single receptor. Instead, amylin receptors are heterodimers formed when the calcitonin receptor associates with one of three receptor-activity-modifying proteins, known as RAMP1, RAMP2, and RAMP3. The pairing changes the receptor's pharmacology, so the same core receptor becomes amylin-responsive depending on which accessory protein it partners with. These complexes are concentrated in hindbrain structures, particularly the area postrema and nucleus tractus solitarius, and in hypothalamic circuits. Activating them produces satiation rather than appetite suppression in the broader sense. The distinction matters. Amylin signalling is the physiological brake that ends a meal, reducing the size of individual eating occasions and slowing gastric emptying, and it also suppresses glucagon after eating. Preclinical work suggests amylin signalling additionally influences leptin sensitivity, which is interesting because leptin resistance is one of the standard explanations for why weight regain is so common. Native amylin is impractical as a drug: it is prone to aggregating into insoluble fibrils, which is the same tendency that produces amyloid deposits in the pancreas in type 2 diabetes. Analogs are therefore engineered for solubility and stability, and long-acting versions add modifications that extend circulation time enough for infrequent administration. Compounds in this group differ mainly in that engineering and in whether they are used alone or paired with a GLP-1 receptor agonist in a fixed combination. The reason for combining the two is that amylin and GLP-1 act on overlapping but distinct circuits, so their effects on food intake can add together rather than simply duplicating each other. That is the explicit design logic behind the combination products in this group. The pathway's clinical standing is intermediate. Amylin biology itself is well established, and an earlier short-acting amylin analog has been an approved medicine for years, so the mechanism is not speculative. The long-acting analogs described here, however, are still working through late-stage clinical development, and their durable benefit and tolerability relative to GLP-1 agonism alone are not yet settled questions. Nausea and vomiting are recognised features of amylin receptor activation, reflecting the same hindbrain circuitry that produces the satiation effect, so the wanted and unwanted effects are not easily separated.
Peptides acting through this pathway.
FAQ.
What does amylin receptor agonism do?
Amylin, also called islet amyloid polypeptide, is co-secreted with insulin from pancreatic beta cells in response to a meal. It does not act through a dedicated single receptor. Instead, amylin receptors are heterodimers formed when the calcitonin receptor associates with one of three receptor-activity-modifying proteins, known as RAMP1, RAMP2, and RAMP3. The pairing changes the receptor's pharmacology, so the same core receptor becomes amylin-responsive depending on which accessory protein it partners with. These complexes are concentrated in hindbrain structures, particularly the area postrema and nucleus tractus solitarius, and in hypothalamic circuits. Activating them produces satiation rather than appetite suppression in the broader sense. The distinction matters. Amylin signalling is the physiological brake that ends a meal, reducing the size of individual eating occasions and slowing gastric emptying, and it also suppresses glucagon after eating. Preclinical work suggests amylin signalling additionally influences leptin sensitivity, which is interesting because leptin resistance is one of the standard explanations for why weight regain is so common. Native amylin is impractical as a drug: it is prone to aggregating into insoluble fibrils, which is the same tendency that produces amyloid deposits in the pancreas in type 2 diabetes. Analogs are therefore engineered for solubility and stability, and long-acting versions add modifications that extend circulation time enough for infrequent administration. Compounds in this group differ mainly in that engineering and in whether they are used alone or paired with a GLP-1 receptor agonist in a fixed combination. The reason for combining the two is that amylin and GLP-1 act on overlapping but distinct circuits, so their effects on food intake can add together rather than simply duplicating each other. That is the explicit design logic behind the combination products in this group. The pathway's clinical standing is intermediate. Amylin biology itself is well established, and an earlier short-acting amylin analog has been an approved medicine for years, so the mechanism is not speculative. The long-acting analogs described here, however, are still working through late-stage clinical development, and their durable benefit and tolerability relative to GLP-1 agonism alone are not yet settled questions. Nausea and vomiting are recognised features of amylin receptor activation, reflecting the same hindbrain circuitry that produces the satiation effect, so the wanted and unwanted effects are not easily separated.
Which peptides act through amylin receptor agonism?
Cagrilintide, CagriSema. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.